Dude, Where’s My SARS?

The release of infectious agents from the lab is not uncommon, but lab-acquired infections are rare.

Written byDan Cossins
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Scanning electron microscope images of Ebola virionsWIKIMEDIA, PLOS BIOLOGYLabs that handle dangerous biological agents like anthrax, SARS, and Ebola accidentally released pathogens 639 times between 2004 and 2010, but reported no thefts and few cases of lab workers being infected, according to statistics released by the Centers for Disease Control and Prevention (CDC). The report, published in the latest issue of Applied Biosafety, comes more than 10 years after a series of anthrax attacks carried out by a government biodefense researcher in 2001, which prompted tighter regulations on research using infectious agents.

Over the 7-year period studied, labs also reported 11 lab-acquired infections—10 bacterial and one fungal. None of the infections proved fatal, and none made the leap to other people. The authors suggest that lab workers were infected by the release of aerosols containing the agents, often created when a sample plate is opened or stirred.

According to the CDC, the infection rate of 1.6 per year was far lower than the rate of general occupational illnesses in science labs. “If you look at the report as a whole, it's a success story,” co-author Robbin Weyant, told the Associated Press. “We have about 10,000 people a year working in these laboratories. To have such a small number of confirmed infections over nearly a decade, I think, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies